Guardant Health, Inc. , established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally.
Guardant Health stock last closed at $161.41, up 0.23% from the previous day, and has increased 163.05% in one year. It has overperformed other stocks in the Diagnostics & Research industry by 1.42 percentage points. Guardant Health stock is currently +202.27% from its 52-week low of $53.40, and -8.59% from its 52-week high of $176.58.
As of Sep 4, 2026, there are 134.2M shares of GH outstanding. The market capitalization of GH is $21.66B. In the past 24 hours, 2.4M GH shares were traded.
You will need a brokerage account to access the NASDAQ market and buy GH stock.
Based on our analysis, eToro is the best online stock brokerage. Here's why:
Get $10 towards your purchase of stock by signing up for an account with eToro today. This offer is only for US users.
Open eToro AccountNow that you've picked your brokerage, you need to fill out some personal info so you are able to invest in GH stock today.
Now that you've finished signing up on the best stock trading app, you need to deposit funds:
Check out the video below for more details depositing funds into your investment account.
After you have decided on the best place to buy Guardant Health stock, it's absolutely critical to analyze their stock prior to buying, so you actually wrap your head around the risk and opportunity.
WallStreetZen was built to help everyday investors do better fundamental analysis.
You can see all of the due diligence checks on GH's stock page.
You can use many financial metrics, analyses, models, and charts to gauge GH's intrinsic value.
You can access additional valuation research on GH's stock here.
Out of 19 Equities analysts who research GH, the consensus analyst rating on Guardant Health is a Strong Buy
Please keep in mind that analyst ratings are not recommendations, nor are they financial advice.
Dan Leonard, a top 9% analyst from RBC Capital maintains GH with a buy rating and raises their GH price target from $185.00 to $200.00, on Jul 31, 2026.
Anthony Petrone, a top 6% analyst from Mizuho maintains GH with a buy rating and raises their GH price target from $175.00 to $200.00, on Jul 31, 2026.
Casey Woodring, a top 19% analyst from JP Morgan maintains GH with a strong buy rating and raises their GH price target from $185.00 to $195.00, on Jul 31, 2026.
Dan Brennan, a top 4% analyst from TD Cowen maintains GH with a strong buy rating and raises their GH price target from $200.00 to $210.00, on Jul 31, 2026.
Luke Sergott, a top 7% analyst from Barclays maintains GH with a strong buy rating and raises their GH price target from $150.00 to $200.00, on Jul 31, 2026.
Barclays's Luke Sergott raised their price target on Guardant Health (NASDAQ: GH) by 33.3% from $150 to $200 on 2026/07/31. The analyst maintained their Strong Buy rating on the stock.
Guardant Health reported its Q2 2026 earnings.
Raising their price target, Sergott looked ahead and said that a "clear path to more material beats andraises" is visible for the quarters ahead.
For Q2 2026, Guardant Health reported:
For FY 2026, management guided:
Co-CEO Helmy Eltoukhy commented: “Our second-quarter performance reflected broad-based momentum across the Guardant portfolio, with revenue increasing 44% year over year.
“Growth was fueled by strong oncology volume, with acceleration across every product.
"The landmark FDA approval of Guardant360 Liquid CDx further strengthens our portfolio and positions us to drive sustained growth in the years ahead.”
You can dive deeper into what analysts are forecasting on the Guardant Health stock forecast page.
Last year, GH revenue was $1.18B. In the past five year, GH's revenue has gone up by 29.6% per year. This was faster than the Diagnostics & Research industry average of 7.15%.
Find out more about GH's earnings and revenue performance here.
Over the past year, insiders at GH have sold more shares than they have bought.
Amirali Talasaz, CEO of GH, was the latest GH insider to sell. They sold $1,517,632.51 worth of GH stock on Aug 21, 2026.
Research more about who owns GH stock here.
No, Guardant Health doesn't provide an income stream by paying out dividends.
One of the biggest reasons eToro is our favorite brokerage is because of its social trading community.
Click below to learn what other traders have to say.
There are two primary order types:
Press the Open button and your broker will place the order.
If you need additional help investing in stocks on eToro, watch the helpful video below:
Now that you own some GH shares, you'll want to stay up-to-date on your stock purchase.
Create a watchlist to track your GH stock.
To summarize, here are the 6 steps you need to take to buy Guardant Health stock right now:
If you require a place to buy stocks, eToro is our recommended option.
Get Started with eToro TodayIf you would like to get updates on your investment in Guardant Health, add GH to your watchlist by clicking the button below.